StockNews.com Downgrades Chimerix (NASDAQ:CMRX) to Sell

StockNews.com cut shares of Chimerix (NASDAQ:CMRX) from a hold rating to a sell rating in a research report report published on Friday morning.

CMRX has been the subject of a number of other research reports. Wedbush reaffirmed an outperform rating and set a $6.00 target price on shares of Chimerix in a report on Monday, February 12th. HC Wainwright reaffirmed a buy rating and set a $11.00 price objective on shares of Chimerix in a research note on Friday, March 1st.

Chimerix Trading Up 0.3 %

CMRX stock opened at $0.95 on Friday. Chimerix has a 12-month low of $0.88 and a 12-month high of $1.57. The business’s 50-day moving average is $1.04 and its 200 day moving average is $1.00. The stock has a market cap of $85.41 million, a price-to-earnings ratio of -1.02 and a beta of 1.13.

Chimerix (NASDAQ:CMRX) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 39.62%. During the same period in the previous year, the company posted ($0.24) earnings per share. As a group, equities analysts forecast that Chimerix will post -0.81 EPS for the current fiscal year.

Institutional Trading of Chimerix

Several large investors have recently added to or reduced their stakes in CMRX. Pale Fire Capital SE raised its holdings in shares of Chimerix by 113.6% during the 4th quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 112,318 shares during the period. Vestal Point Capital LP purchased a new position in Chimerix during the fourth quarter worth about $1,348,000. Vance Wealth Inc. acquired a new position in Chimerix in the 4th quarter valued at about $46,000. Assenagon Asset Management S.A. grew its stake in shares of Chimerix by 17.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 499,391 shares of the biopharmaceutical company’s stock valued at $481,000 after buying an additional 72,719 shares during the period. Finally, RA Capital Management L.P. acquired a new stake in shares of Chimerix during the 3rd quarter worth approximately $6,240,000. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.